DS
TRVI icon

David Shaw’s Trevi Therapeutics TRVI Stock Holding History

David Shaw’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.26M Buy
281,996
+100,652
+56% +$1.46M ﹤0.01% 2358
2026
Q1 		$2.16M Buy
181,344
+40,032
+28% +$448K ﹤0.01% 2852
2025
Q4 		$1.77M Buy
+141,312
New +$1.63M ﹤0.01% 3144

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

David Shaw's TRVI Position: Q2 2026 in Review

David Shaw increased its Trevi Therapeutics (TRVI) stake by 56% in Q2 2026, buying an estimated $1.46M and bringing the position to 281,996 shares worth $5.26M. The position accounts for ﹤0.01% of the portfolio, ranked #2358.

David Shaw first reported a position in TRVI in Q4 2025 and has held it in 3 quarters since. 217 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • David Shaw held 281,996 shares of Trevi Therapeutics worth $5.26M as of Q2 2026.
  • David Shaw bought 100,652 Trevi Therapeutics shares in Q2 2026, an estimated $1.46M.
  • Trevi Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #2358 holding.
  • David Shaw first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 217 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.